Milestone outlines ~2-year phase III AFib-RVR timeline as CARDAMYST launch reaches ~600 prescriptions

Q1 2026 Management View “This is an exciting day as it represents our first analyst call reporting on our first ever quarter or, more accurately, partial quarter of sales since the commercial launch ...

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoption Express Scripts national formulary coverage secured as company ...
Nasdaq

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...
Seeking Alpha

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

MONTREAL and CHARLOTTE, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (MIST) today reported financial results for the second quarter ended June 30, 2024 and provided a ...
Seeking Alpha

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil ...